PolyNovo's Pivot: Execution, PMA, and a Broader Complex-Wound Platform
Record U.S. June, MTX 90% growth, and a finalized pivotal trial mark the start of a conversion phase beyond large burns.
PNV.AX · Earnings Call · 2026-08-25
The Year of Conversion
PolyNovo's FY26 results read as a deliberate shift from building capability to converting it into outcomes. Newly appointed CEO Bruce Peatey framed it clearly: “FY '27 is less about building capability and more about converting that capability into outcomes.” — Bruce Peatey, Chief Executive Officer · 2026-08-25 That conversion is visible across the numbers: group sales of $138.4M, up 21.3% in constant currency, with a record June in the U.S. and a July group record already in the bank. The company's complex wound franchise is now the real growth driver, with a 52.8% 3-year CAGR outside large burns, while NovoSorb MTX grew 89.6% to $12.6M. This broadening beyond the historical large-burn base is the key change: PolyNovo is no longer a single-indication story.Catalysts: PMA and SynPath
The most significant milestone is the finalization of the U.S. pivotal RCT clinical study report. Bruce confirmed: “The clinical study report for the U.S. pivotal RCT is now finalized, representing an important milestone for PolyNovo.” — Bruce Peatey, Chief Executive Officer · 2026-08-25 The PMA submission is expected by year-end, with FDA review likely around 12 months, which would open the deep-burn indication and unlock reimbursement. In parallel, the company is preparing to launch SynPath into the U.S. outpatient market. "Commercial readiness is underway," Bruce noted, with the product already holding an HCPCS code. The outpatient push, initially targeting hospital outpatient departments, leverages the existing surgeon relationships and broadens the addressable market beyond the inpatient setting.The financials reinforce the execution story. Adjusted EBITDA rose 50.4% to $13.4M, while free cash flow turned positive at $9.4M—a major milestone after years of heavy investment. The cost discipline is evident: corporate admin and overhead costs were down 1.1% on a constant-currency basis, and the U.S. sales team's productivity is increasing. CFO Jan-Marcel Gielen emphasized that the bottom line is now highly leveraged to sales growth, as demonstrated by the 50% EBITDA jump on modest revenue growth.
Perhaps the most striking evidence of the platform's traction is the clinical and educational adoption. BTM was included in 9 published textbook chapters in FY26 alone, versus just 1 across all prior years. And the health economics work with IQVIA is building the reimbursement case for broader use—a critical step for market access. As Bruce put it:
Our focus remains on delivering meaningful clinical impact, scaling globally and unlocking the full value of the NovoSorb platform.
The strategic pivot is also visible in the innovation pipeline. With a new Chief Scientific Officer, Marthe D'Ombrain, the company is re-instilling discipline and velocity, prioritizing products like hernia repair and breast reconstruction that address high-clinical-need, high-commercial-return indications. Management is explicitly shifting R&D resources away from PMA preparation (~5% of sales expected next year) and towards next-generation products. The decision to expand beyond burns—into trauma, reconstruction, and limb salvage—is a deliberate bet on a $2B+ total addressable market. The U.S. trajectory, with 200 new hospital accounts added during the year, now exceeds 880 total accounts, and the non-burn category is growing at a 52.8% 3-year CAGR, confirming that complex wound applications are already a material growth engine, not a future story.
What's changed at PolyNovo is not just the numbers—it's the mindset. The new leadership is focused on execution, operating leverage, and converting clinical credibility into commercial scale. With record sales momentum, a finalized pivotal trial, and a clear roadmap for PMA approval and SynPath launch, FY27 is set to be the year the company's broader ambitions start to materialize.